Dr Chen completed his postdoctoral training at the University of Utah  and has over 20 years of work experience in the pharmaceutical industry. He has extensive experience in new drug research, discovery, and clinical development for indications such as osteoporosis, osteoarthritis, metastatic bone disease and oncology. 

He used to be a Senior Scientist in the R&D Department at the headquarters of Merck & Co., Inc. During his 10-year tenure, he was mainly responsible for the clinical trials (Phase I and Phase III) of project products Odanacatib and MK-0764. To date, the drug Odanacatib completed Phase II trials for the treatment of metastatic bone disease (MBD) in 2008 and Phase III clinical trials for the treatment of osteoporosis in 2016; the drug MK-0764 completed Phase III clinical trials for the treatment of osteoarthritis in 2017. He has published a total of 4 papers on the research results of these projects in journals including <JBMR>, <Bone>, and <Bone Report>. 

Dr Chen has also participated in the preparation of WMA (World Market Application) documents for the Odanacatib product, making significant contributions to the registration of Odanacatib in multiple countries.